VECT News and Press, VectivBio Holding AG From 09/21/21

BASEL, Switzerland, Sept. 21, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced...

BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced upcoming investor events. ...

BASEL, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Paul R. Carter and Dr. Murray W. S...

- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline - - VectivBio to Host R&D Day on September 21, 2021- BASEL, Switzerland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a cli...

Gainers: AFRM +32.4%. MNTS +11.8%. KPLT +10.5%.  VECT +5.2%. OSUR +3.9%. Losers: TSP -10.6%. LTCH -6.8%. LTRPA -4.8%. ENVX -4.3%. RDHL -3.2%. For further details see: AFRM, MNTS, TSP and LTCH among after hours movers

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions, today published ...

- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on September 2, 2021 - BASEL, Switzerland, July 12, 2021 (GLOBE NEWSWIRE) -- Vect...

VectivBio Holding (VECT) announces that the U.S. FDA has granted orphan drug designation to apraglutide for the prevention of acute graft-versus-host disease ((aGVHD)).The FDA’s Orphan Drug Designation program is designed to advance the development of drugs and biologics intended to tr...

BASEL, Switzerland, June 24, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare c...

VectivBio Holding ([[VECT]] +1.9%) has dosed the first patient in its Phase 2 STARS Nutrition metabolic balance study evaluating apraglutide in colon-in-continuity ((CIC)) patients with short bowel syndrome with intestinal failure (SBS-IF). This Phase 2 trial is designed to evaluate the effic...